Inflammatory markers and endothelial dysfunction markers in patients with inflammatory bowel disease
https://doi.org/10.31146/1682-8658-ecg-242-10-116-121
Abstract
In patients with IBD the most sensitive markers of ED are VCAM-1, ICAM-1 and vWF, whose levels increase during the active phase and decrease during remission. CRP shows a stable correlation with Crohn’s disease activity, but is less predictive in ulcerative colitis. Levels of ET-1 in IBD remain relatively unchanged; however, changes are observed in experimental models of colitis and in chronic uveitis. ADMA shows ambiguous results in IBD but is elevated in isolated uveitis manifestations, indicating systemic inflammation even in clinically localized lesions.
About the Authors
L. V. Tarasova
Chuvash State University n.a. I.N. Ulyanov
Russian Federation
Russian Federation
A. A. Nikolaev
Chuvash State University n.a. I.N. Ulyanov
Russian Federation
Russian Federation
Yu. V. Tsyganova
Chuvash State University n.a. I.N. Ulyanov
Russian Federation
Russian Federation
References
1. Clinical guidelines. Ulcerative colitis. K51. 2024. All-Russian public organization "Association of Coloproctologists of Russia", Russian Gastroenterological Association.@@ Клинические рекомендации. Язвенный колит. K51. 2024. Общероссийская общественная организация «Ассоциация колопроктологов России», Российская Гастроэнтерологическая Ассоциация.
2. Clinical guidelines. Crohn's disease. K50. 2024. All-Russian public organization "Association of Coloproctologists of Russia", Russian Gastroenterological Association.@@ Клинические рекомендации. Болезнь Крона. K50. 2024. Общероссийская общественная организация «Ассоциация колопроктологов России», Российская Гастроэнтерологическая Ассоциация.
3. Badimon L, Pena E, Arderiu G, Padro T, Slevin M, Vilahur G, et al. C-reactive protein in atherothrombosis and angiogenesis. Front Immunol. 2018;9:430. doi:10.3389/fimmu.2018.00430
4. Hein TW, Singh U, Vasquez-Vivar J, Devaraj S, Kuo L, Jialal I. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis. 2009 Sep;206(1):61-8. doi:10.1016/j.atherosclerosis.2009.02.002.
5. Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. Endothelin. Pharmacol Rev. 2016;68(2):357-418. doi:10.1124/pr.115.011833
6. Banecki KMRM, Dora KA. Endothelin-1 in Health and Disease.Int J Mol Sci. 2023;24:11295. doi:10.3390/ijms241411295
7. Haydinger CD, Ashander LM, Tan ACR, Smith JR.Intercellular Adhesion Molecule 1: More than a Leukocyte Adhesion Molecule. Biology. 2023;12:743. doi:10.3390/biology12050743
8. Furuta K, Guo Q, Pavelko KD, Lee JH, Robertson KD, Nakao Y, et al. Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis. J Clin Invest. 2021 Mar 15;131(6): e143690. doi:10.1172/JCI143690. PMID:33476308; PMCID: PMC7954604
9. Ley K, Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest. 2001 May;107(10):1209-10. doi:10.1172/JCI13005.
10. Guo X, Xing Y, Jin W. Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023;14:1183586. doi:10.3389/fendo.2023.1183586
11. Huang SS, Huang WC, Tsai CT, et al. Plasma asymmetric dimethylarginine is associated with vulnerable plaque and long-term outcomes in stable coronary artery disease. Sci Rep. 2023;13:7541. doi:10.1038/s41598-023-32728-9
12. Jones SC, Banks RE, Haidar A, Gearing AJ, Hemingway IK, Ibbotson SH, et al. Adhesion molecules in inflammatory bowel disease. Gut. 1995 May;36(5):724-30. doi:10.1136/gut.36.5.724.
13. Nielsen OH, Brynskov J, Vainer B. Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis. Dig Dis Sci. 1996 Sep;41(9):1780-5. doi:10.1007/BF02088745.
14. Gu P, Theiss A, Han J, Feagins LA. Increased Cell Adhesion Molecules, PECAM-1, ICAM-3, or VCAM-1, Predict Increased Risk for Flare in Patients With Quiescent Inflammatory Bowel Disease. J Clin Gastroenterol. 2017 Jul;51(6):522-527. doi:10.1097/MCG.0000000000000618.
15. Soriano A, Salas A, Sans M, Gironella M, Elena M, Anderson DC, et al. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest. 2000 Oct;80(10):1541-51. doi:10.1038/labinvest.3780164.
16. Cartland R, Burns R, et al. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn’s disease in mice. Gastroenterology. 2001;121(6):1428-1436
17. Cibor D, Owczarek D, Butenas S, Salapa K, Mach T, Undas A. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases. World J Gastroenterol. 2017 Jul 14;23(26):4796-4805. doi:10.3748/wjg.v23.i26.4796.
18. Meucci G, Pareti F, Vecchi M, Saibeni S, Bressi C, de Franchis R. Serum von Willebrand factor levels in patients with inflammatory bowel disease are related to systemic inflammation. Scand J Gastroenterol. 1999 Mar;34(3):287-90. doi:10.1080/00365529950173708.
19. McCartney SA, Ballinger AB, Vojnovic I, Farthing MJ, Warner TD. Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzenesulphonic acid-induced colitis. Life Sci. 2002 Sep 6;71(16):1893-904. doi:10.1016/s0024-3205(02)01923-9.
20. Korkmaz H, Asıl M, Temel T, Öztürk B, Kebapçılar L. Evaluation of serum neutrophil gelatinase-associated lipocalin (NGAL), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) levels, and their relations with disease type and activity in inflammatory bowel diseases. Turk J Med Sci. 2021 Oct 21;51(5):2403-2412. doi:10.3906/sag-2103-220. PMID:33984894
21. Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2010 Jan;16(1):52-7. doi:10.1002/ibd.20994.
22. Clough J, Colwill M, Poullis A, Pollok R, Patel K, Honap S. Biomarkers in inflammatory bowel disease: a practical guide. Therap Adv Gastroenterol. 2024 May 9;17:17562848241251600. doi:10.1177/17562848241251600. PMID:38737913; PMCID: PMC11085009
23. Ishida N, Miyazu T, Suzuki T, Tamura S, Tani S, Yamade M, et al. Evaluation of the modified Crohn’s disease activity index in patients with Crohn disease with enterostomy: A single-center observational study. Medicine (Baltimore). 2021 Feb 12;100(6): e24717. doi:10.1097/MD.0000000000024717
24. Peyrin-Biroulet L, Reinisch W, Colombel J, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut. 2014;63:88-95
25. Koczka C, Goodman A, Abramowitz M, Jain P. Are Inflammatory Markers Predictive of Length of Hospital Stay in Patients with Inflammatory Bowel Disease?: 1162. Am J Gastroenterol. 2010;105(Suppl): S421
26. Guclu H, Gurlu V.Comparison of corneal endothelial cell analysis in patients with uveitis and healthy subjects.Int Ophthalmol. 2019;39. doi:10.1007/s10792-017-0809-7
27. Sayed O, Abdel-Magied R, Elela M, Abdel-Nasser A. Value of Serum Asymmetric Dimethylarginine (ADMA) As a Novel Biomarker for Uveitis in Behçet’s Disease. Ocul Immunol Inflamm. 2024;33:1-7. doi:10.1080/09273948.2024.2342378
28. Klok AM, Luyendijk L, Zaal MJ, Rothova A, Kijlstra A. Soluble ICAM-1 serum levels in patients with intermediate uveitis. Br J Ophthalmol. 1999 Jul;83(7):847-51. doi:10.1136/bjo.83.7.847.
29. Powierza K, Sawicka-Powierza J, Urban B, Żelazowska-Rutkowska B, Cylwik B, Mikołuć B, et al. Endothelin-1 Serum Concentration in Pediatric Chronic Idiopathic Uveitis. Clin Ophthalmol. 2021 Jan 12;15:157-164. doi:10.2147/OPTH.S276109.
Review
For citations:
Tarasova L.V., Nikolaev A.A., Tsyganova Yu.V. Inflammatory markers and endothelial dysfunction markers in patients with inflammatory bowel disease. Experimental and Clinical Gastroenterology. 2025;(10):116-121. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-242-10-116-121
Views:
5
JATS XML
Email this article 
